Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment
Archiv der Pharmazie · 2023
DOI: 10.1002/ardp.202300137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Noura S Hanafy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Novel thiazolidine‐2,4‐diones have been developed and estimated as conjoint inhibitors of EGFR T790M and VEGFR‐2 against HCT‐116, MCF‐7, A549, and HepG2 cells. Compounds 6a, 6b , and 6c were known to be the dominant advantageous congeners against HCT116 (IC 50 = 15.22, 8.65, and 8.80 µM), A549 (IC 50 = 7.10, 6.55, and 8.11 µM), MCF‐7 (IC 50 = 14.56, 6.65, and 7.09 µM) and HepG2 (IC 50 = 11.90, 5.35, and 5.60 µM) mass cell lines, correspondingly. Although compounds 6a, 6b , and 6c disclosed poorer effects than sorafenib (IC 50 = 4.00, 4.04, 5.58, and 5.05 µM) against the tested cell sets, congeners 6b and 6c demonstrated higher actions than erlotinib (IC 50 = 7.73, 5.49, 8.20, and 13.91 µM) against HCT116, MCF‐7 and HepG2 cells, yet lesser performance on A549 cells. The hugely effective derivatives 4e–i and 6a–c were inspected versus VERO normal cell strains. Compounds 6b, 6c, 6a , and 4i were found to be the most effective derivatives, which suppressed VEGFR‐2 by IC 50 = 0.85, 0.90, 1.50, and 1.80 µM, respectively. Moreover, compounds 6b, 6a, 6c , and 6i could interfere with the EGFR T790M performing strongest effects with IC 50 = 0.30, 0.35, 0.50, and 1.00 µM, respectively. What is more, 6a, 6b , and 6c represented satisfactory in silico computed ADMET profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Omar Almukhtar University, Libya.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
- Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, Saudi Arabia.
- Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Hanafy, N. S., Aziz, N. A. A. M., El-Hddad, S. S. A., Abdelgawad, M. A., Ghoneim, M. M., Dawood, A. F., Mohamady, S., El-Adl, K., & Ahmed, S. (2023). Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300137
Vancouver
Hanafy NS, Aziz NAAM, El-Hddad SSA, Abdelgawad MA, Ghoneim MM, Dawood AF, et al. Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300137
BibTeX
@article{Hanafy2023,
author = {Hanafy, Noura S and Aziz, Nada A A M and El-Hddad, Sanadelaslam S A and Abdelgawad, Mohamed A and Ghoneim, Mohammed M and Dawood, Amal F and Mohamady, Samy and El-Adl, Khaled and Ahmed, Sahar},
title = {Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment},
journal = {Archiv der Pharmazie},
year = {2023},
doi = {10.1002/ardp.202300137}
}
EUVIMED